Inarigivir soproxil

Research use only, not for human use.

Inarigivir soproxil (SB-9200, SB9200, Inarigivir, ORI-9020) is an orally bioavailable dinucleotide that activates RIG-I and NOD2, induces interferon mediated antiviral immune responses.

Inarigivir soproxil (SB-9200, SB9200, Inarigivir, ORI-9020) is an orally bioavailable dinucleotide that activates RIG-I and NOD2, induces interferon mediated antiviral immune responses; shows broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, RSV and influenza, and also demonstrates activity HBV in vitro and in vivo; a novel agonist of innate immunity, and prodrug of Inarigivir (ORI-9020;SB-9000).HBV Infection Phase 2 Clinical(In Vitro):Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways.Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 μM, and EC90s of 8.0 and 6.0 μM for genotype 1A and 1B, respectively.Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense.(In Vivo):The induction of host immune responses by pretreatment with Inarigivir soproxil (SB 9200) followed by Entecavir (ETV) resulted in antiviral efficacy that was superior to that obtained using the strategy of viral reduction with ETV followed by immunomodulation.Sequential treatment of chronic WHV carrier woodchucks with Inarigivir soproxil (30 mg/kg)followed by ETV induced marked suppression of serum viremia and antigenemia and delayed recrudescence of viral replication compared to sequential treatment with ETV followed by Inarigivir soproxil.

Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 μM, and EC90s of 8.0 and 6.0 μM for genotype 1A and 1B, respectively.Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense.

The induction of host immune responses by pretreatment with Inarigivir soproxil (SB 9200) followed by Entecavir (ETV) resulted in antiviral efficacy that was superior to that obtained using the strategy of viral reduction with ETV followed by immunomodulation.Sequential treatment of chronic WHV carrier woodchucks with Inarigivir soproxil (30 mg/kg)followed by ETV induced marked suppression of serum viremia and antigenemia and delayed recrudescence of viral replication compared to sequential treatment with ETV followed by Inarigivir soproxil. Animal Model:Woodchucks chronically infected with woodchuck hepatitis virus (WHV)Dosage:30 mg/kg Administration: Orally treated once daily; group 1 received ETV for 4 weeks followed by Inarigivir soproxil for 12 weeks. Group 2 received Inarigivir soproxil for 12 weeks followed by ETV for 4 weeks Result:Both groups demonstrated marked reductions in hepatic WHV nucleic acid levels which were more pronounced in Group 2.

SB-9200 | SB9200 | Inarigivir | ORI-9020

Immunology/Inflammation

RLR

RLR

Infection

——

942123-43-5

703.617

C25H34N7O13PS

>98% (HPLC)

10 mM in DMSO

O[C@@H](C[C@@H](N1C2=C(C(N)=NC=N2)N=C1)O3)[C@@H]3COP(O[C@@H]4[C@@H](CC)O[C@@H](N5CCC(NC5=O)=O)[C@@H]4OC)(SCOC(OC(C)C)=O)=O

(((((2S,3S,5S)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl)oxy)phosphoryl)thio)methyl isopropyl carbonate

(-20℃)

With Ice Pack

≥ 2 years